From Yahoo Finance: 2025-04-08 11:48:00

Belluscura’s stock price plummeted by nearly 50% after scrapping its 2025 guidance due to Trump’s 54% tariffs on Chinese goods. The UK-founded medical device company, listed on the LSE, develops portable oxygen concentrators. Revenue forecasts of over $16m were affected, leading to a stock drop to £0.65 per share.

Trump remains steadfast on tariffs, citing the need to fix global trade. Some countries, like the UK and Saudi Arabia, face a 10% baseline tariff, while the EU, Japan, and China face increases of 20%, 24%, and 54% respectively. China retaliated with a 34% tariff on US imports, prompting threats of additional US tariffs.

China vows to fight against what they call “naked extortion” and “utterly absurd” logic regarding tariffs. If China doesn’t withdraw its 34% increase, the US plans to impose a 50% tariff on Chinese imports. This could bring total tariffs on China to 104%, escalating tensions between the two nations.

Read more: Belluscura stock plummets by 50% after nixing annual forecast amid Trump tariffs